- $93.09m
- $92.54m
- $27.64m
Immucell down after FDA says cow disease drug application is incomplete
Brief: Immucell Announces Unaudited Financial Results For The Second Quarter Ended June 30, 2021
Brief: ImmuCell Says Expects To Reduce Backlog Of Orders During Q3
Brief: Immucell Announces Unaudited Financial Results For The First Quarter Ended March 31, 2021
Brief: ImmuCell Announces Preliminary, Unaudited Sales Results For Q1 of 2021
Brief: ImmuCell Makes Important Regulatory Submission
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:51 PM
Brief: Immucell Says Sees 12% Increase In Total Product Sales To About $15.3 Mln During Year Ended December 31, 2020
Brief: ImmuCell Announces Preliminary, Unaudited Sales Results For The Year Ended December 31, 2020
Brief: Immucell Corp Announces Restructuring Of Its Bank Debt
Brief: ImmuCell Reports Q3 Loss Per Share Of $0.04
Brief: Immucell Reports Total Product Sales Rose 25% To $3.7 Mln During 3-Month Period Ended Sept. 30
NASDAQ RESUMED AT 11:20 AM
NASDAQ RESUMED AT 11:10 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:05 AM
Brief: Immucell Corp Reports Reduced Backlog Of Orders Worth About $945,000 As Of June 30, 2020
Brief: ImmuCell Q1 Loss Per Share $0.02
Brief: ImmuCell Q4 Loss Per Share $0.04
Brief: ImmuCell Reports Q4 Loss Per Share $0.06